CD14+ Cell Culture for NKT Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing NKT cell ligand-pulsed cells are inefficient and require a long time, limiting their ability to effectively activate NKT cells for cancer and infectious disease treatment.
Innovation Solution
Culturing CD14 positive cells in a medium containing NKT cell ligands and GM-CSF, but without IL-4, to produce NKT cell ligand-pulsed CD14 positive cells that can strongly activate NKT cells, inducing proliferation, IFN-γ production, and cytotoxic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce NKT cell ligand-pulsed cells, then the cells can be produced, but the production time is long and efficiency is low
Solution Approach 1:
The invention changes the chemical parameters of the culture medium by specifying exact concentrations of GM-CSF (10-100 ng/mL) and α-GalCer (1-100 μg/mL), and by controlling the culture temperature (37°C) and CO2 concentration (5%). These parameter optimizations enable efficient NKT cell activation and IL-2 production within 48-72 hours, significantly improving productivity while reducing production time compared to conventional methods
2Reliability
If α-GalCer is administered alone, then NKT cells are activated, but both IFN-γ and IL-4 are produced which cancel each other's effects
Solution Approach 1:
The invention uses dendritic cells as an intermediary carrier to deliver α-GalCer to NKT cells in a controlled manner. The dendritic cells take up α-GalCer, process it, and present it to NKT cells through CD1d molecules, enabling selective activation of NKT cells to produce IFN-γ without the counteracting IL-4 production that occurs with direct α-GalCer administration
Solution Approach 2:
The invention achieves local quality control by concentrating the immune response at specific sites where dendritic cells present α-GalCer to NKT cells. This localized presentation ensures that NKT cells are activated in a controlled environment, producing primarily IFN-γ rather than the mixed cytokine response seen with systemic α-GalCer administration
3Reliability
If dendritic cells are used to pulse NKT cell ligands, then NKT cell activation is enhanced, but the production process becomes more complex
Solution Approach 1:
The invention makes dendritic cells universally applicable by establishing a standardized culture protocol that works consistently across different batches and laboratories. The medium composition (RPMI-1640 with 10% FBS, GM-CSF at 10-100 ng/mL, and α-GalCer at 1-100 μg/mL) and culture conditions (37°C, 5% CO2 for 48-72 hours) are optimized to produce dendritic cells with consistent NKT cell activation capacity, reducing operational complexity
Data Source
AI summary
The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-γ production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.